View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 24, 2020

AliveCor’s KardiaMobile 6L wins approval for use in Covid-19 patients

AliveCor’s KardiaMobile 6L technology has received the US Food and Drug Administration (FDA) approval to measure QTc and detection of potentially dangerous QT prolongation in coronavirus (Covid-19) patients.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Follow the latest updates of the outbreak on our timeline.


AliveCor’s KardiaMobile 6L technology has received the US Food and Drug Administration (FDA) approval to measure QTc and detection of potentially dangerous QT prolongation in coronavirus (Covid-19) patients.

The heart rate corrected interval QTc reflects the integrity of the heart’s electrical recharging system.

Its abnormal prolongation can stem from congenital long QT syndrome, many disease states and electrolyte abnormalities. It can also be caused by several of the FDA-approved medications.

Patients with a prolonged QTc are at a risk for Torsades de Pointes that can cause sudden cardiac arrest or even sudden cardiac death (SCD).

The company noted that the drugs being used off-label to treat Covid-19 have the potential for unwanted QT prolongation and drug-induced SCD (DI-SCD) in patients.

The drugs include Hydroxychloroquine and Azithromycin.

AliveCor CEO Priya Abani said: “At AliveCor, we are committed to providing life-saving cardiological services to those who need them most. The benefits of remote, personal ECG measurement have never been clearer.

“We are thankful to the FDA for issuing timely guidance to help expand the availability of our device to assist in the treatment of Covid-19 during this global health emergency.”

KardiaMobile 6L is considered to be six-lead personal ECG. It helps in obtaining the patient’s QTc as a vital sign to allow rapid and safe use of the drugs.

In addition, the technology will allow ECG technicians to collect QTc without exposing them to the affected patients.

The immediate availability of the device is expected to bring down the life-threatening effects of Covid-19 drugs.

AliveCor expects to add a professional QTc monitoring service soon. It will facilitate a seamless workflow with no on-premise calculations required.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network